Kamada (NASDAQ:KMDA) Stock Passes Below 200-Day Moving Average – What’s Next?

Kamada Ltd. (NASDAQ:KMDA) shares crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $7.05 and traded as low as $6.82. Kamada shares last traded at $6.82, with a volume of 22,720 shares.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of Kamada in a research note on Wednesday, October 8th. Three investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, Kamada presently has an average rating of “Moderate Buy” and an average price target of $13.00.

Kamada Stock Down 1.4%

The company has a market cap of $392.22 million, a price-to-earnings ratio of 20.06, a PEG ratio of 0.70 and a beta of 0.84. The business has a 50-day simple moving average of $6.92 and a two-hundred day simple moving average of $7.05.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported $0.13 EPS for the quarter, beating analysts’ consensus estimates of $0.09 by $0.04. Kamada had a return on equity of 7.41% and a net margin of 11.22%.The business had revenue of $44.75 million for the quarter, compared to analyst estimates of $158.59 million. Kamada has set its FY 2025 guidance at EPS. As a group, equities analysts anticipate that Kamada Ltd. will post 0.23 earnings per share for the current year.

Institutional Trading of Kamada

A number of institutional investors and hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC lifted its stake in shares of Kamada by 3.1% in the second quarter. Acadian Asset Management LLC now owns 263,556 shares of the biotechnology company’s stock worth $2,053,000 after buying an additional 7,925 shares during the last quarter. ARK Investment Management LLC acquired a new stake in shares of Kamada in the second quarter worth $1,972,000. Huntleigh Advisors Inc. lifted its stake in shares of Kamada by 4.3% in the third quarter. Huntleigh Advisors Inc. now owns 141,562 shares of the biotechnology company’s stock worth $982,000 after buying an additional 5,786 shares during the last quarter. Jane Street Group LLC acquired a new stake in shares of Kamada in the first quarter worth $582,000. Finally, Goldman Sachs Group Inc. acquired a new stake in shares of Kamada in the first quarter worth $497,000. 20.38% of the stock is currently owned by institutional investors and hedge funds.

About Kamada

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite.